Viatris lifts full-year outlook despite flat sales and loss, as Pacira deal nears close

Viatris has told the market it expects to finish 2026 somewhat stronger than previously signalled, raising the midpoints of its full-year guidance even though third-quarter sales were unchanged from a year earlier. Revenue for the three months came to $3.75bn, the company said on 5 November.

The quarter ended in the red on a GAAP basis, with a net loss of $325m. Adjusted EBITDA, the measure the company uses to strip out certain items, was $1.20bn. The announcement as summarised to us does not break out what drove the loss or the guidance change, and the specific guidance ranges were not available to us.

The most significant corporate event ahead is the planned purchase of Pacira BioSciences, which Viatris expects to complete by the end of November. No deal terms were included in the material we reviewed.

Viatris also reported several product milestones. The US Food and Drug Administration has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for adults with presbyopia, the common loss of close-up focusing that comes with ageing. WAKIX has received approval in Japan, and the Gwyn Lo contraceptive patch went on sale in the US in October. Pricing, labelling details and launch timing for RYZUMVI were not provided.